GSK’s Jideytro Shows 94% Response in ROS1 Lung Cancer
London, United Kingdom, September 13, 2026 GSK has announced positive registrational data from the Phase I/II ARROS-1 trial supporting...
Phase I/II trial
Advertisement
Xodus Medical Study Validates Hot Pink Pad Performance
PITTSBURGH, Pa., July 23, 2026 Xodus Medical has announced encouraging results from a new observational clinical study demonstrating that...
Natera Partners with Diakonos Oncology to Evaluate Signatera in Refractory Melanoma Trial
AUSTIN, Texas | May 2026 Natera, Inc. announced a new collaboration with Diakonos Oncology Corp. to utilize its personalized...
Faron Launches BLAZE Trial to Overcome Immunotherapy Resistance
TURKU, Finland; LONDON, United Kingdom — December 22, 2025 — Faron Pharmaceuticals Ltd, a clinical-stage biopharmaceutical company, has announced...
Advertisement
